Literature DB >> 14991744

Inactivation of the cyclin-dependent kinase inhibitor 2A (CDKN2A) gene in squamous cell carcinoma of the larynx.

Robert Smigiel1, Maria Sasiadek, Tomasz Krecicki, David Ramsey, Jozef Jagielski, Nikolaus Blin.   

Abstract

Defects in the system controlling the cell cycle can lead an increased proliferation of cancer cells. The aim of our study was to analyze the relationship between genetic changes leading to inactivation of the CDKN2A gene and subsequent alteration of protein expression in squamous cell cancer of the larynx (SCCL) in connection with the clinical and histopathological course of the disease. Analysis was carried out on DNA isolated from the blood and primary larynx cancer cells of 62 patients. To investigate loss of heterozygosity (LOH), PCR fragment analysis was applied. The size and quantity of fluorescent PCR products were evaluated in an automated sequencer. Specific chemical methylation with sodium bisulfite in a sequential PCR reaction (MSP) was applied to analyze promoter methylation. Cancer tissue sections served to determine the level of protein expression with immunohistochemical (IHC) staining and commercial antibodies. LOH at the CDKN2A locus was observed in 55.35% of the informative cases. Aberrant methylation was found in 37.5% and a decreased level of protein expression observed in 45% of all informative cases. Whenever P16 expression was decreased, LOH and promoter hypermethylation at CDKN2A were observed with a frequency of 73.33% and 80.95%, respectively (Fisher's test, P<0.005). Sixty-nine percent of G3 tumors had at least one genetic alteration at CDKN2A, compared with 40.9% of G1 cancers. The results indicate that CDKN2A inactivation played a significant role in the development of squamous cell carcinoma of the larynx. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2004        PMID: 14991744     DOI: 10.1002/mc.20007

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  7 in total

1.  Mutational Status of CDKN2A and TP53 Genes in Laryngeal Squamous Cell Carcinoma.

Authors:  Teodora A Todorova; Stanislav H Jordanov; Gergana S Stancheva; Ivan J Chalakov; Mincho B Melnicharov; Kuncho V Kunev; Vanio I Mitev; Radka P Kaneva; Teodora E Goranova
Journal:  Pathol Oncol Res       Date:  2014-08-23       Impact factor: 3.201

2.  Expression of the tumor suppressor gene hypermethylated in cancer 1 in laryngeal carcinoma.

Authors:  Jarosław Markowski; Aleksander L Sieroń; Katarzyna Kasperczyk; Monika Ciupińska-Kajor; Aleksandra Auguściak-Duma; Wirginia Likus
Journal:  Oncol Lett       Date:  2015-02-25       Impact factor: 2.967

3.  A common variant of CDKN2A (p16) predisposes to breast cancer.

Authors:  T Debniak; B Górski; T Huzarski; T Byrski; C Cybulski; A Mackiewicz; S Gozdecka-Grodecka; J Gronwald; E Kowalska; O Haus; E Grzybowska; M Stawicka; M Swiec; K Urbański; S Niepsuj; B Waśko; S Góźdź; P Wandzel; C Szczylik; D Surdyka; A Rozmiarek; O Zambrano; M Posmyk; S A Narod; J Lubinski
Journal:  J Med Genet       Date:  2005-05-06       Impact factor: 6.318

4.  Role of DNA methylation in head and neck cancer.

Authors:  Semra Demokan; Nejat Dalay
Journal:  Clin Epigenetics       Date:  2011-07-09       Impact factor: 6.551

5.  Epigenetic dysregulation in laryngeal squamous cell carcinoma.

Authors:  Thian-Sze Wong; Wei Gao; Zeng-Hong Li; Jimmy Yu-Wai Chan; Wai-Kuen Ho
Journal:  J Oncol       Date:  2012-05-07       Impact factor: 4.375

Review 6.  Overview on Molecular Biomarkers for Laryngeal Cancer: Looking for New Answers to an Old Problem.

Authors:  Michela Falco; Chiara Tammaro; Takashi Takeuchi; Alessia Maria Cossu; Giuseppe Scafuro; Silvia Zappavigna; Annalisa Itro; Raffaele Addeo; Marianna Scrima; Angela Lombardi; Filippo Ricciardiello; Carlo Irace; Michele Caraglia; Gabriella Misso
Journal:  Cancers (Basel)       Date:  2022-03-28       Impact factor: 6.639

7.  Some molecular and clinical aspects of genetic predisposition to malignant melanoma and tumours of various site of origin.

Authors:  Tadeusz Debniak
Journal:  Hered Cancer Clin Pract       Date:  2007-06-15       Impact factor: 2.857

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.